Trachoma, caused by repeated ocular infection with Chlamydia trachomatis (Ct), is targeted for elimination as a public health problem. Serological testing for antibodies is promising for surveillance; determining useful thresholds will require collection of serological data from settings with different prevalence of the indicator trachomatous inflammation-follicular (TF). Dried blood spots were collected during trachoma mapping in two districts each of Togo and Democratic Republic of the Congo. Anti-Ct antibodies were detected by multiplex bead assay (MBA) and three different lateral flow assays (LFA) and seroprevalence and seroconversion rate (SCR) were determined. By most tests, the district with > 5% TF (the elimination threshold) had five-sixfold higher seroprevalence and tenfold higher SCR than districts with < 5% TF. The agreement between LFA and MBA was improved using a black latex developing reagent. These data show optimization of antibody tests against Ct to better differentiate districts above or below trachoma elimination thresholds.
Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo
Gwyn, S., Awoussi, M. S., Bakhtiari, A., Bronzan, R. N., Crowley, K., Harding-Esch, E. M., Kassankogno, Y., Kilangalanga, J. N., Makangila, F., Mupoyi, S., Ngondi, J., Ngoyi, B., Palmer, S., Randall, J. M., Seim, A., Solomon, A. W., Stewart, R., Togbey, K., Uvon, P. A., & Martin, D. L. (2021). Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo. Scientific Reports, 11(1), . https://doi.org/10.1038/s41598-021-86639-8
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.
Spatiotemporal trends in three smoothed overdose death rates in US counties, 2012-2020
Improving text classification with Boolean retrieval for rare categories
COVID-19 diagnosis and SARS-CoV-2 strain identification by a rapid, multiplexed, point-of-care antibody microarray